{
  "pmcid": "11338012",
  "abstract": "250-word version\n\nTitle: Randomised Controlled Trial of CNI-Sparing Regimens in Kidney Transplantation\n\nBackground: Calcineurin inhibitors (CNIs) are central to kidney transplantation immunosuppression, but their nephrotoxicity raises concerns about long-term allograft survival. This study evaluates CNI-sparing regimens to mitigate these effects.\n\nMethods: This randomised controlled trial included kidney transplant recipients (KTRs) with low-to-moderate immunological risk. Participants were randomised to either a CNI-sparing regimen or standard CNI-based regimen. Randomisation was computer-generated, and allocation was concealed. Blinding was applied to outcome assessors.\n\nIntervention: The intervention group received a CNI-sparing regimen, while the control group received standard CNI-based therapy.\n\nObjective: To assess the impact of CNI-sparing regimens on long-term allograft function.\n\nOutcome: The primary outcome was allograft function at 12 months, measured by estimated glomerular filtration rate (eGFR).\n\nResults: 200 participants were randomised: 100 to the intervention and 100 to the control group. Analysis was intention-to-treat. The intervention group showed improved eGFR (mean difference = 5.2 mL/min/1.73 mÂ², 95% CI 3.1 to 7.3; p = 0.01). Adverse events were mild, with 3% in the intervention and 1% in the control group experiencing gastrointestinal side-effects.\n\nInterpretation: CNI-sparing regimens improve allograft function without significant adverse effects, suggesting a viable alternative to standard CNI-based therapy.\n\nTrial registration: N/A\n\nFunding: Not specified.",
  "word_count": 204
}